PER.C6ARG cells as a serum-free suspension cell platform for the production of high titer poliovirus: A potential low cost of goods option for world supply of inactivated poliovirus vaccine

• Published in: Vaccine Vol. 31; no. 5; pp. 850 - 856
• Main Authors: Sanders, Barbara P, Edo-Matas, Diana, Custers, Jerome HHV, Koldijk, Martin H, Klaren, Vincent, Turk, Marije, Luitjens, Alfred, Bakker, Wilfried AM, Uytdehaag, Fons, Goudsmit, Jaap, Lewis, John A, Schuitemaker, Hanneke
• Format: Journal Article
• Language: English
• Published: 21.01.2013
• Subjects: Poliovirus
• ISSN: 0264-410X

There are two highly efficacious poliovirus vaccines: Sabin's live-attenuated oral polio vaccine (OPV) and Salk's inactivated polio vaccine (IPV). OPV can be made at low costs per dose and is easily administrated. However, the major drawback is the frequent reversion of the OPV vaccine strains to virulent poliovirus strains which can result in Vaccine Associated Paralytic Poliomyelitis (VAPP) in vaccinees. Furthermore, some OPV revertants with high transmissibility can circulate in the population as circulating Vaccine Derived Polioviruses (cVDPVs). IPV does not convey VAPP and cVDPVs but the high costs per dose and insufficient supply have rendered IPV an unfavorable option for low and middle-income countries.